International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) in collaboration with Dhaka North City Corporation (DNCC) and Expanded Programme on Immunization of Bangladesh commenced a typhoid conjugate vaccine effectiveness study on Monday.
The study is a part of the Typhoid Vaccine Acceleration Consortium (TyVAC) project, in which researchers are conducting studies to evaluate just how much typhoid can be prevented by the typhoid conjugate vaccine in Bangladesh.
The study will be carried out among 43,350 children between 9 months and under 16 years of age, living in Mirpur of the capital, said a press release of the icddr,b.
The statement of the icddr,b said typhoid fever is caused by a bacterium, Salmonella enterica serovar Typhi and is a major cause of illness; children and adolescents are mostly affected.
Globally, about one hundred and fifty thousand patients die due to typhoid every year, it added.
Earlier, studies have confirmed bacteremic typhoid fever incidence of 3.9 episodes per 1,000 person-years during fever surveillance in a Dhaka urban slum.
Two old typhoid vaccines are already prequalified by the World Health Organisation (WHO) for prevention and protection from typhoid, however these are not included in the routine immunization programme of Bangladesh.
These are not licensed nor are they effective for infants and young children. The new single-dose injectable typhoid conjugate vaccine will be used in the study.
This vaccine was prequalified by the WHO in December 2017 and has been found to be safe and effective and already licensed in India and Nepal and 20,000 children have already been safely vaccinated in Nepal.
Other collaborating institutes include the University of Oxford, UK, the University of Maryland, USA, and PATH and the study is supported by the Bill and Melinda Gates Foundation..